[Treatment of ancylostomiasis with a combination of thiabendazole-levamisole (200 ccases)].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000350:Africa, Central; D000354:Africa, Western; D000562:Amebiasis / Q000188:drug therapy; D000724:Ancylostomiasis / Q000188:drug therapy*; D000871:Anthelmintics / Q000008:administration & dosage* / Q000009:adverse effects; D001196:Ascariasis / Q000188:drug therapy; D002648:Child; D004338:Drug Combinations; D005260:Female; D005368:Filariasis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010270:Parasite Egg Count; D012552:Schistosomiasis / Q000188:drug therapy; D013322:Strongyloidiasis / Q000188:drug therapy; D013827:Thiabendazole / Q000008:administration & dosage* / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D014900:West Indies
D000871:Anthelmintics; D004338:Drug Combinations; D013844:Thiazoles; D013827:Thiabendazole
Traitement de l'ankylostomiase par l'association thiabendazole-lévamisole (a propos de 200 cas.